» Articles » PMID: 7728570

Parietal Pleurectomy for Malignant Pleural Effusion

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 1995 Mar 1
PMID 7728570
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Malignant pleural effusions are seen frequently in clinical practice and are most commonly caused by breast cancer and lung cancer. Standard treatment usually consists of complete drainage of the pleural space via a chest tube and instillation of a pleural irritant to obtain pleural symphysis. In a majority of instances, such treatment effectively controls the pleural space; however, standard treatment fails in some cases.

Methods: Twenty-four patients who did not respond to standard treatment for malignant pleural effusion were subjects for parietal pleurectomy, which was usually performed through an axillary thoracotomy. In several cases, decortication was also necessary. The study population was composed of 18 women and six men. Twelve of the patients had carcinoma of the breast, five carcinoma of the lung, and four carcinoma of the ovary.

Results: Three patients died in the perioperative period to give an operative mortality of 12.5%. The other 21 patients all had satisfactory control of their recurrent malignant effusions. Their survival time ranged from 2 to 30 months (average 10.6).

Conclusions: Parietal pleurectomy is an effective operation for recurrent malignant pleural effusion. However, because of its significant morbidity and mortality, it should be reserved for failures of standard treatment, and patient selection is important.

Citing Articles

Making cold malignant pleural effusions hot: driving novel immunotherapies.

Murthy P, Ekeke C, Russell K, Butler S, Wang Y, Luketich J Oncoimmunology. 2019; 8(4):e1554969.

PMID: 30906651 PMC: 6422374. DOI: 10.1080/2162402X.2018.1554969.


Symptomatic Fluid Drainage: Tunneled Peritoneal and Pleural Catheters.

Ha T, Madoff D, Li D Semin Intervent Radiol. 2017; 34(4):337-342.

PMID: 29249857 PMC: 5730441. DOI: 10.1055/s-0037-1608704.


Non-intubated video-assisted thoracic surgery as the modality of choice for treatment of recurrent pleural effusions.

Cox S, Katlic M Ann Transl Med. 2015; 3(8):103.

PMID: 26046044 PMC: 4436415. DOI: 10.3978/j.issn.2305-5839.2015.04.22.


Malignant pleural effusions: appropriate treatment approaches.

Aydin Y, Turkyilmaz A, Intepe Y, Eroglu A Eurasian J Med. 2015; 41(3):186-93.

PMID: 25610100 PMC: 4261269.


The treatment of pleural carcinosis with malignant pleural effusion.

Ried M, Hofmann H Dtsch Arztebl Int. 2013; 110(18):313-8.

PMID: 23720697 PMC: 3659961. DOI: 10.3238/arztebl.2013.0313.


References
1.
Webb W, Ozmen V, Moulder P, Shabahang B, Breaux J . Iodized talc pleurodesis for the treatment of pleural effusions. J Thorac Cardiovasc Surg. 1992; 103(5):881-5; discussion 885-6. View

2.
Ponn R, Blancaflor J, DAgostino R, Kiernan M, TOOLE A, Stern H . Pleuroperitoneal shunting for intractable pleural effusions. Ann Thorac Surg. 1991; 51(4):605-9. DOI: 10.1016/0003-4975(91)90319-l. View

3.
Tsang V, Fernando H, Goldstraw P . Pleuroperitoneal shunt for recurrent malignant pleural effusions. Thorax. 1990; 45(5):369-72. PMC: 462476. DOI: 10.1136/thx.45.5.369. View

4.
Keller S . Current and future therapy for malignant pleural effusion. Chest. 1993; 103(1 Suppl):63S-67S. DOI: 10.1378/chest.103.1_supplement.63s. View

5.
Austin E, Flye M . The treatment of recurrent malignant pleural effusion. Ann Thorac Surg. 1979; 28(2):190-203. DOI: 10.1016/s0003-4975(10)63779-4. View